- This Sunday, as women script history, NDA readies for a tactical shift
- R-Day violence: Delhi HC junks plea seeking punishment for police officials
- Waterlogging, power cuts in Chennai as rain woes continue for residents
- Ex-CBDT chairman PC Mody appointed as new secretary general of Rajya Sabha
- MGNREGS ensured work for a year, now states are running out funds for it
- SC adjourns hearing in Lakhimpur Kheri case till Nov 15 on UP govt request
- MP considering ban on Salman Khurshid's book on Ayodhya verdict: Minister
- Retail direct, integrated ombudsman scheme will make country stronger: Modi
- Passenger vehicle wholesales down by 27% in October amid chip shortage
- Naveen Patnaik dedicates 142 schools in five Odisha districts
LIVE: 11 more women army officers to get PC in 10 days, Centre tells SC
Covaxin, a vaccine developed in India, was found to have a 77.8 per cent efficacy rate against symptomatic Covid-19, said The Lancet
Topics
Today News | Coronavirus | Vodafone Idea
BS Web Team |
Last Updated at November 12, 2021 15:14 IST
EVENT HIGHLIGHTS
A view of the Supreme Court | Photo: PTI
Negotiators at the UN climate summit in Glasgow are expected to lock horns on Friday for what is scheduled to be the final day of bargaining over how to stop global warming from becoming catastrophic.
Tata Steel has reported a consolidated net profit of Rs 11,918 crore in the September quarter, up nearly eight-fold or 661 per cent from the same period last year. The company overtook Tata Consultancy Services (TCS) to become the most profitable company in the Tata Group.
Covaxin, a vaccine developed by India’s government medical research agency and Bharat Biotech International Ltd., was found to have a 77.8 per cent efficacy rate against symptomatic Covid-19 in an analysis published in The Lancet. "Further research is needed to determine the vaccine’s long-term safety and effectiveness…,” said the journal.
CATCH ALL THE LIVE UPDATES
Auto Refresh Load More
Copyrights © 2021 Business Standard Pvt Ltd. All rights reserved.